• CHE

Earnings call: Chemed reports mixed Q3 results, VITAS growth amid Roto-Rooter dip

Chemed Corporation's Q3 2024 results show VITAS Healthcare growth contrasted by Roto-Rooter challenges, leading to adjusted EPS guidance of $23-$23.15 amid mixed performance across segments.